drugset / Trial / NCT01074073

Lithium Drug-Drug Interaction Study With Lurasidone HCl

NCT01074073

Phase 1 Completed 24 enrolled Sumitomo Pharma America, Inc.
RandomizedSingle-groupOpen-label

Summary

The purpose of this study is to evaluate the drug-drug interaction effect between Lithium and Lurasidone HCl.

Timeline

Start
2008-08
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lithium Unknown 600 mg Oral
Subject Lurasidone Small molecule 120 mg Oral

Indications